- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03671499
A Study for Testing Text Messaging and Newsletter as a Strategy for Interrupting Sedentary Behavior (SLMM)
A Pilot Study for Testing the Feasibility and Efficacy of Text Messaging and Newsletter as a Strategy for Interrupting Sedentary Behavior (Sit Less, Move More)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators are conducting a pilot study to examine the feasibility and efficacy of a technology-based behavior change intervention for reducing SB in African Americans with MS located in the United States. The intervention combines text message- and print-based approaches for behavior change based on Social Cognitive Theory (SCT). SCT-based content will be the active component for changing SB, while cellphone text messages and print newsletter will be the delivery mechanism. The use of cellphone to deliver the intervention content is based, in part, on the fact that cellphone is an ordinary form of communication in today's world, providing an optimal medium for reaching large groups of people remotely. The study will yield major advancement in identifying the feasibility and efficacy of interrupting and reducing SB via a technology-based intervention in African Americans with MS, a segment of the MS population that has been underrepresented in MS therapeutic management studies. If successful, this research will lay the foundation for applying the current strategy in large-scale interventions including African Americans and possibly other minority groups with MS.
The intervention will be 12 weeks and divided into two parts. Part 1: Weeks 1-6 will focus on interrupting long periods of SB. At the beginning of the first week, participants will receive a packet containing print material providing lay information on what constitutes SB and examples of such behavior, highlighting the importance of interrupting prolonged periods of SB and the associated health benefits. The aim of the packet is to provide the basis to introduce the key element (i.e., SCT-based instructional cellphone text-messages) of the intervention. This will occur during the following six weeks, wherein participants will receive two text-messages/day (i.e., morning and afternoon) on the importance and health benefits of interrupting SB hourly. The text-messages will prompt individuals to interrupt SB by standing still, standing while performing tasks, or walking around. The text-messages will include further tips and strategies for interrupting SB. The investigators have previously developed a computerized messaging system that will be used to send the text-messages twice a day in the proposed intervention. The investigators will supplement the text messaging by sending bi-weekly SCT-based newsletters to participants that highlight ways of overcoming difficulties in effectively interrupting SB. The SCT content for the messages and newsletter has been created in previous research and will be revised for the proposed intervention. Part 2: Weeks 7-12 will focus on replacing SB with light PA. On the first day of week 7, participants will receive a second packet of print material explaining the concept of light PA and emphasizing the importance of moving more daily. The print material will highlight the benefits of replacing SB with light PA and will contain instructions for goal setting (i.e., target number of steps/day) and self-monitoring of daily PA, including receive a pedometer and a log for recording total steps/day. Similar to part 1, the key element for intervention delivery will be the SCT-based instructional cellphone text-messages, which participants will receive during the second six-week intervention period. More specifically, they will receive two text-messages/day on the importance and health benefits of replacing SB with light PA. The text-messages will recommend participants to watch for prolonged periods of SB and try and substitute these for light PA, such as light intensity walking and light-intensity focal exercise (e.g., stationary walk, marching). The text-messages will also remind participants to use the pedometer to set incremental personal goals for steps/day and to gauge the replacement of SB with light PA by watching the pedometer readings. The investigators further will include tips and strategies for replacing SB with light PA based on common daily activities. Bi-weekly SCT-based newsletters will be used to supplement the stimulus from the text-messages, by reinforcing the importance of sitting less and moving more.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- University of Alabama Birmingham
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- African American
- Definite diagnosis of MS
- Relapse free in the last 30 days
- Ambulatory with or without assistance
- Having a Patient-Determined Disease Steps score of 0-5
- Daily engagement in sedentary behavior ≥ 480 min/day
- Health contribution score of <14 calculated from the Godin Leisure-Time Exercise Questionnaire
- Absence of major musculoskeletal problems, and/or cardiovascular, cardiopulmonary, and/or metabolic diseases that can influence physical activity and sedentary behavior levels
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Social Cognitive Theory based text messages
The study only contains 1 arm.
All participants will receive the same experimental protocol.
Participants will receive daily text messages and bi-weekly newsletters for reducing sedentary behavior based on Social Cognitive Theory.
|
Participants receive daily text messages and bi-weekly newsletters with information about reducing sitting behavior and increasing physical activity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in sedentary behavior evaluated with activity monitors
Time Frame: Assessments will be conducted at baseline and at the midpoint of the experiment (intervention week 6)
|
Activity monitors are Actigraph accelerometers that participants will wear on an elastic belt around their waist for 7 days.
These activity monitors measure how frequently and how much an individual moves.
|
Assessments will be conducted at baseline and at the midpoint of the experiment (intervention week 6)
|
|
Change in sedentary behavior evaluated with activity monitors
Time Frame: Assessments will be conducted at the midpoint of the intervention (intervention week 6) and at at the end of the intervention (immediately after intervention week 12).
|
Activity monitors are Actigraph accelerometers that participants will wear on an elastic belt around their waist for 7 days.
These activity monitors measure how frequently and how much an individual moves.
|
Assessments will be conducted at the midpoint of the intervention (intervention week 6) and at at the end of the intervention (immediately after intervention week 12).
|
|
Change in sedentary behavior evaluated with activity monitors
Time Frame: Assessments will be conducted at baseline and at at the end of the intervention (immediately after intervention week 12).
|
Activity monitors are Actigraph accelerometers that participants will wear on an elastic belt around their waist for 7 days.
These activity monitors measure how frequently and how much an individual moves.
|
Assessments will be conducted at baseline and at at the end of the intervention (immediately after intervention week 12).
|
|
Change in physical activity evaluated with activity monitors
Time Frame: Assessments will be conducted at baseline and at the midpoint of the experiment (intervention week 6)
|
Activity monitors are Actigraph accelerometers that participants will wear on an elastic belt around their waist for 7 days.
These activity monitors measure how frequently and how much an individual moves.
|
Assessments will be conducted at baseline and at the midpoint of the experiment (intervention week 6)
|
|
Change in physical activity evaluated with activity monitors
Time Frame: Assessments will be conducted at the midpoint of the intervention (intervention week 6) and at at the end of the intervention (immediately after intervention week 12).
|
Activity monitors are Actigraph accelerometers that participants will wear on an elastic belt around their waist for 7 days.
These activity monitors measure how frequently and how much an individual moves.
|
Assessments will be conducted at the midpoint of the intervention (intervention week 6) and at at the end of the intervention (immediately after intervention week 12).
|
|
Change in physical activity evaluated with activity monitors
Time Frame: Assessments will be conducted at baseline and at at the end of the intervention (immediately after intervention week 12).
|
Activity monitors are Actigraph accelerometers that participants will wear on an elastic belt around their waist for 7 days.
These activity monitors measure how frequently and how much an individual moves.
|
Assessments will be conducted at baseline and at at the end of the intervention (immediately after intervention week 12).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Life will be evaluated with the 36-Item Short Form Health Survey (SF-36 questionnaire).
Time Frame: Assessments will be conducted at baseline and at the midpoint of the experiment (intervention week 6)
|
The SF-36 questionnaire is a 36 item self-report questionnaire designed to assess patient health status.
The questionnaire is scored on 8 sections: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health.
Scores are transformed into a 0-100 scale with 0 equivalent to maximum disability and 100 equivalent to no disability.
|
Assessments will be conducted at baseline and at the midpoint of the experiment (intervention week 6)
|
|
Quality of Life will be evaluated with the 36-Item Short Form Health Survey (SF-36 questionnaire).
Time Frame: Assessments will be conducted at the midpoint of the intervention (intervention week 6) and at at the end of the intervention (immediately after intervention week 12).
|
The SF-36 questionnaire is a 36 item self-report questionnaire designed to assess patient health status.
The questionnaire is scored on 8 sections: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health.
Scores are transformed into a 0-100 scale with 0 equivalent to maximum disability and 100 equivalent to no disability.
|
Assessments will be conducted at the midpoint of the intervention (intervention week 6) and at at the end of the intervention (immediately after intervention week 12).
|
|
Quality of Life will be evaluated with the 36-Item Short Form Health Survey (SF-36 questionnaire).
Time Frame: Assessments will be conducted at baseline and at at the end of the intervention (immediately after intervention week 12).
|
The SF-36 questionnaire is a 36 item self-report questionnaire designed to assess patient health status.
The questionnaire is scored on 8 sections: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health.
Scores are transformed into a 0-100 scale with 0 equivalent to maximum disability and 100 equivalent to no disability.
|
Assessments will be conducted at baseline and at at the end of the intervention (immediately after intervention week 12).
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Robert W Motl, PhD, University of Alabama at Birmingham
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0000518843
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Social Cognitive Theory based text messages
-
Muhammet Faruk YigitNot yet recruitingAging | Health Behavior | Self Efficacy | Health LiteracyTurkey (Türkiye)
-
Gazi UniversityCompletedSocial Cognitive Theory-Based Educational Intervention Program on Sustainable Eco-Friendly NutritionSelf Efficacy | Adolescent Nutrition | Sustainable Eco-Friendly NutritionTurkey (Türkiye)
-
University of OklahomaRecruitingChemotherapy Side Effects | Cancer SurvivorshipUnited States
-
Palo Alto Medical FoundationNational Heart, Lung, and Blood Institute (NHLBI)CompletedLung Diseases | Asthma
-
NYU Langone HealthCompletedObesity | Type 2 Diabetes | Chronic Kidney Disease (CKD)United States
-
University of California, BerkeleyCompleted
-
Fadime KoyuncuCompletedPatient Engagement | Self Efficacy | Foot Ulcer, Diabetic | Wound Healing | NursingTurkey
-
NYU Langone HealthCompleted
-
University of GlasgowCompletedCovid19 | VaccinationUnited Kingdom